ASCLETIS-B(01672): The weight loss effect of ASC47 combined with semaglutide in obese subjects is relatively increased by up to 56.2% compared to semaglutide monotherapy.

ASCLETIS-B (01672) announced that on the 29th day, the candidate drug ASC47, which reduces weight without reducing muscle, when used in combination with semaglutide in obese subjects (body mass index 30kg/m), showed a relative increase in weight loss efficacy of up to 56.2% compared to the placebo and semaglutide combination (semaglutide monotherapy). The ASC47-103 study (NCT06972992) is a randomized, double-blind, placebo-controlled study conducted in the United States to evaluate the safety, tolerability, and efficacy of a single subcutaneous injection of ASC47 compared to volume-matched placebo and semaglutide (0.5 mg, once a week, four doses) in obese subjects. The treatment period is 4 weeks with a follow-up period of 6 weeks. The study was conducted in the United States and included a total of 28 obese subjects. The study objectives include safety, tolerability, pharmacokinetics, and evaluation of weight loss efficacy of three different doses of ASC47 (10 mg, 30 mg, and 60 mg) in combination with semaglutide (0.5 mg, once a week, four doses). Due to the short treatment period (28 days), the study did not include an evaluation of the effects of ASC47 on fat and muscle mass. "As the first study to evaluate the combination of a fat-targeted THR agonist and an intestinal incretin drug in obese subjects, we are pleased to see that the combination of the fat-targeted THR agonist ASC47 with intestinal incretin therapy has produced a significant synergistic weight loss effect, with a relative increase in weight loss efficacy of up to 56.2%, and a substantial improvement in gastrointestinal tolerability," said Dr. Jinzi Wu, Founder, Chairman and CEO of Gleyos, "This study provides important proof of concept data that will serve as a key basis for the design of our subsequent Phase IIb combination drug studies, including for obesity and metabolic associated fatty liver disease (MAFLD) and other metabolic diseases."